Dr. Robert Figlin Describes the Efficacy of AGS-003 in mRCC

Dr. Figlin Describes the Efficacy of AGS-003 in mRCCПодробнее

Robert Figlin, MD, Steven Spielberg Family Chair of Hematology Oncology, Discusses the Issue of CostПодробнее

Dr. Figlin on Ongoing ADAPT Trial for mRCCПодробнее

Dr. Figlin on Advances in Immunotherapy for Kidney CancerПодробнее

Robert Figlin, MD, discusses sequencing when treating metastatic RCC patientsПодробнее

Copy of Dr. Figlin Discusses the Future of Kidney Cancer TreatmentПодробнее

Dr. Robert Figlin on the Future of Treatment for Patients with RCCПодробнее

Dr. Figlin on Intermediate Prognosis Patients With mRCCПодробнее

Dr. Robert Figlin on The Increasingly Complicated Treatment Paradigm for Renal Cell CarcinomaПодробнее

Dr. Figlin Discusses Future of RCC TreatmentПодробнее

Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patientsПодробнее

Robert A. Figlin, MD, regarding the role of systemic therapy in oligometastatic RCCПодробнее

Dr. Figlin on TKI Therapy Options in Renal Cell CarcinomaПодробнее

Robert Glanzman, MD: Overview of CNM-Au8Подробнее

Dr. Figlin on Advice for Oncologists Treating RCCПодробнее

Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCCПодробнее

Dr. Figlin on the Evolving Treatment Landscape of Renal Cell CarcinomaПодробнее

Robert A. Figlin, MD, speculates on clinical advances in renal cell carcinomaПодробнее